Los puntos clave no están disponibles para este artículo en este momento.
The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.
Parmentier et al. (Fri,) studied this question.